Use of Peripheral Blood Mononuclear Cells As BiOmarkers of DiaBetic CardIomyopathy
Type 2 diabetes (T2D), especially when associated with metabolic syndrome (MS) is at high risk to develop heart failure with preserved ejection fraction (HFpEF) or heart failure with mildly reduced ejection fraction (HFmrEF), and the specific impact of T2D+MS in cardiac function impairment is usually known as diabetic cardiomyopathy (DC). Cardiac remodelling (ie hypertrophy) and subtle myocardial dysfunction are highly prevalent in T2D+MS but not specific enough to predict further HFpEF or HFmrEF. Also, current biomarkers can identify but do not predict HFpEF or HFmrEF in T2D patients; Furthermore, specific biomarkers are needed. Peripheral blood mononuclear cells (PBMC) obtained from a peripheral blood sample can provide insights from calcic and inflammatory pathways, and may identify more specific molecular signatures shared between T2D+MS and HFpEF.
• Patient coming for a scheduled cardiology or endocrinology visit as part of their follow-up
• Patient coming on an empty stomach for the blood test
• Male or female aged between 40 and 80 inclusive
• Patient without systemic disease and/or without anti-inflammatory treatment
• Patient not objecting to this research
• Patient accepting the conservation of biological samples and the performance of genetic analyzes
⁃ Group 1: No-T2D +MS / No-HF (control group)
• Patient without T2D or MS and without heart failure coming to a consultation or day hospital for another reason (e.g. screening for atypical symptom, etc.)
⁃ Group 2: No-T2D +MS / HFpEF or HFmrEF
• Patient without T2D or MS
• HFpEF or HFmrEF. diagnosed
⁃ Group 3: T2D+MS / no-HF
• Patient diagnosed with T2D+MS
⁃ Group 4: T2D +MS / HFpEF or HFmrEF
• Patient diagnosed with T2D and MS
• HFpEF or HFmrEF. diagnosed